Proya takes a 19% stake in Bio-Meso, positioning itself in efficacy skincare through a non-consolidated approach and laying out a second growth curve.
As the domestic beauty market fully enters deep water characterized by heavy R&D investment and a battle for mindshare over ingredients, this low-key capital move placed by Proya through its investment platform clearly outlines the defensive counterattack trajectory of a leading domestic beauty company on the eve of the dividend from a single main brand peaking. For the 19% minority equity investment in the efficacy skincare brand BIO-MESO, on the surface it appears to be a financial injection that does not interfere with daily operations and is not included in consolidated financial statements; in reality, it is Proya's typical tactical positioning move after the myths of blockbuster products such as Ruby and Double Anti, attempting to complete the puzzle of segmented professional skincare through an external buyer model.
In the rapidly changing beauty consumer market, no single brand can forever occupy the commanding heights of traffic and consumer groups. Proya, which in earlier years relied on a blockbuster product strategy and extreme Douyin operations to achieve a leap in revenue to tens of billions, now likewise faces the realistic interrogation of an aging customer base for its main brand, intensifying involution in the anti-aging track, and continuously declining ROI in customer acquisition and traffic investment. BIO-MESO, by entering through oily acne-prone skin, sensitive skin repair, and hardcore molecular ingredients, has accumulated extremely solid vertical word-of-mouth among young geeks and ingredient-focused circles.
For Proya, which seeks to tear off the mass fast-moving consumer goods label and evolve into a high-end and multi-brand group, building a segmented mindshare brand from scratch carries extremely high trial-and-error costs; borrowing capital to directly insert into the segmented leader has become the lightest shortcut.
Equity Structure: 19% Shareholding and Capital Isolation Through Non-Consolidation
Examining the organizational structure of this transaction along the capital veins penetrated through business registration, the delicate balancing of control rights and profit distribution between the two parties is clearly traceable in Tianyancha records. Tianyancha business registration data shows that the core entity behind BIO-MESO, Shanghai Kedai Biotechnology Co., Ltd., underwent equity changes, and Proya (Hainan) Investment Co., Ltd. formally took the position of second-largest shareholder with a 19% shareholding ratio.
In the equity map penetrated by Tianyancha, this investment platform is wholly controlled by the A-share listed company Proya Cosmetics Co., Ltd. Founder Shi Nuo holds approximately 47.06% and still firmly controls the position of largest shareholder and actual controller of the company.
The 19% shareholding ratio and the official statement of non-consolidation demonstrate Proya's extremely seasoned thinking on capital isolation.
On the one hand, the soul of a cutting-edge beauty brand is highly dependent on the founding team's keen touch in product definition, community sentiment, and avant-garde visuals. Once a listed company forcibly takes full control and dispatches traditional professional managers to take over, it is very easy to kill the brand's original personality amid cumbersome financial reimbursements and KPI assessments. Retaining the founding team's leadership can maximize the preservation of BIO-MESO's purity and R&D vitality in the mindshare of ingredient-focused consumers.
On the other hand, this minority equity structure without consolidation builds a natural firewall for Proya on the financial side. At present, consumer goods investment and financing have long bid farewell to wild galloping; after experiencing early community explosion, cutting-edge skincare brands often hit a scale ceiling in crossing from tens of millions to hundreds of millions in revenue. If a full acquisition were made rashly, not only would the listed company need to bear a huge goodwill impairment exposure, but it could also be dragged down in net profit margin performance by the new brand's early R&D and channel trial-and-error.
By entering with a 10% to 20% equity stake, Proya both locks in a future priority acquisition right and strictly confines operating risk within the investment income account.
Hidden Exchange of Supply Chain and R&D
Deeper synergy lies hidden in the supply chain foundation and the concealed exchange of R&D resources.
As a typical cutting-edge independent brand, BIO-MESO's long-term pain point lies in its lack of supply chain bargaining power comparable to a tens-of-billions-level giant and the capital strength to build large raw material factories itself, leaving it consistently constrained in customized raw material purity, packaging material procurement costs, and nationwide offline distribution channels. After Proya's equity investment, even without participating in consolidation, its powerful supply chain manufacturing base, raw material centralized procurement network, and negotiating chips with leading e-commerce platforms can all empower BIO-MESO at extremely low friction cost;
And BIO-MESO's cutting-edge exploration of specific active targets and microecological skincare can, in turn, provide differentiated perspectives for Proya's R&D technology reserves.